Novavax COVID-19 vaccine: FDA authorizes fourth shot for adults

COVID-19 vaccine choice as the Food and Drug Administration on Wednesday cleared Novavax shots for adults.Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S. -- and one that’s already available in Europe and multiple other countries.Nearly a quarter of American adults still haven't gotten their primary vaccinations even this late in the pandemic, and experts expect at least some of them to roll up their sleeves for a more conventional option — a protein-based vaccine.The Maryland company also hopes its shots can become a top booster choice in the U.S.

and beyond. Tens of millions of Americans still need boosters that experts call critical for the best possible protection as the coronavirus continues to mutate.For now, the FDA authorized Novavax's initial two-dose series for people 18 and older.RELATED: COVID-19 omicron subvariants BA.4 and BA.5 could be ‘worst’ so far, doctors say"I encourage anyone who is eligible for, but has not yet received, a COVID-19 vaccine to consider doing so," FDA Commissioner Dr.

Robert Califf said in a statement.Before shots begin, the Centers for Disease Control and Prevention must recommend how they should be used, a decision expected next week.Novavax CEO Stanley Erck told The Associated Press that he expected the U.S.

to expand use of the vaccine beyond unvaccinated adults fairly quickly.RELATED: Pharmacists can prescribe COVID treatment drug Paxlovid, FDA saysAlready the FDA is evaluating it for those as young as 12, Erck said.